SHIRE PLC - Blocklisting - Interim Review

Block Listing SIX MONTHLY RETURN

November 23, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of applicant:		Shire plc
Name of scheme:		Shire Sharesave Scheme
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		184,913
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		302
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		184,611

   

Name of applicant:		Shire plc
Name of scheme:		Shire Portfolio Share Plan
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		1,204,351
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		434,736
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		769,615

   

Name of applicant:		Shire plc
Name of scheme:		Shire Employee Stock Purchase Plan
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		244,451
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		394
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		244,057

   

Name of applicant:		Shire plc
Name of scheme:		Shire Long Term Incentive Plan 2015
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		2,955,872
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		119,460
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		2,836,412

   

Name of applicant:		Shire plc
Name of scheme:		Shire Global Employee Stock Purchase Plan
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		1,999,969
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		395,726
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		1,604,243

 

Name of applicant:		Shire plc
Name of scheme:		Baxalta Exchange Awards
Period of return:	From:	June 15, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		N/A
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		25,000,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		4,511,796
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		20,488,204

   

Name of contact:	Sarah Rixon, Company Secretarial Assistant
Telephone number of contact:	01256 894000

For further information please contact:

Investor Relations
Sarah Elton-Farr	[e-mail]	[phone]
Ian Karp	[e-mail]	[phone]
Robert Coates	[e-mail]	[phone]
Media
Lisa Adler	[e-mail]	[phone]
Debbi Ford	[e-mail]	[phone]

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Copyright r 23 PR Newswire